Date: December 8-9, 2021 Venue: Hybrid, San Diego, CA The forthcoming Social Media Strategies Summit – Public Agencies & Government event will be held in an entirely digital format on December 8-9, 2021, by the Global Strategic Management Institute (“GSMI”), a cutting-edge conference production business focused on encouraging disruptive innovation. The virtual event is designed to help government agencies use social media to humanize their offices and engage with their communities. Attendees will have access to a carefully curated series of sessions and experienced speakers who will seek to address topics that can have the greatest impact on a social media strategy in the public sector. Senior-level marketing professionals choose SMSsummit year after year to stay up to date on the newest in social media marketing. This December 8-9, 2021, at SMSS Public Agencies and Government, use social media to humanize your agency and engage your communities! Some highlights of the event include:

• Learn new social media methods and share your experiences.
• Make connections with other government employees.
• Get answers to all of your social media questions.
• Learn how to deal with problems using techniques and recommendations.

Why Should You Attend It? SMSsummit is a great place to go for new social media ideas and community-building tactics. It brings together government and public-sector colleagues from around the world to share experiences and learn new social media methods.  Make connections with government employees from all over the country. The Social Media Strategy Summit offers an opportunity to get all of your social media questions answered through speaker Q&A, live chat, and discussions with other attendees. Make social media a point of pride for your team! This event will assist you in laying the groundwork for a long-term, scalable social media policy that allows your team to provide the best possible service to your constituents. Learn techniques and tips for dealing with the most pressing issues facing government agencies, such as social media and crisis communications, boosting agency reputation, and cultivating community partnerships. Examine and evaluate your current social media efforts. In an era where openness and authenticity are more crucial than ever, learn how to humanize your organization and gain public trust. In addition to the live presentations, the Social Media Strategy Summit will provide attendees with the opportunity to network with agency peers from across the country, allowing conference delegates to share their experiences and learn new social media strategies alongside their fellow public sector colleagues from across the US and around the world in a seamless virtual forum. For more information, please visit https://ibn.fm/YgsQR

Date: December 7-9 Venue: Virtual The forthcoming Accredited Investors Virtual Expo will be held in a completely digital format on December 7-9, 2021, by MoneyShow, a major producer of financial conferences for affluent investors, active traders, and financial advisors. Different economic and market conditions have been known to benefit different asset classes in the past. At the Accredited Investors Expo, investors and guests will learn innovative ways to diversify their portfolios for better yields, appreciation, and diversity. The Accredited Investors Virtual Expo gives conference registrants direct access to the financial industry’s greatest brains via live presentations, allowing them to interact with financial experts and fellow investors in real time. Investors will discover how to invest in esoteric private-market topics, how to exploit new crowdfunding rules to find tomorrow’s market unicorns, why preferred equity reigns supreme for today’s educated investors, and why a little bitcoin may go a long way. Here you will learn about: 

• How to Avoid Market Excesses in 2021 and Beyond
• Pre-IPO Private Placements: High Returns and High Risks
• How to Invest in Private-Market Niche Topics
• What US Investors Should Know About Private Placements in Other Countries
• Navigating 2021 in the Face of Washington’s and the Economy’s Disruption
• Pursuing Tomorrow’s Market Unicorns Using the New Crowdfunding Rules
• Accredited Investors Have a New Option in Rolling Venture Funds
• Not going out and buying the dips

More than 35 prominent market analysts, money managers, and investing gurus will present real-time analysis, guidance, and methods aimed to uncover and capitalize on opportunities across a variety of under-the-radar industries at this year’s event. Why Should You Visit It: MoneyShow has a long history of helping people become great investors and traders by providing timely investing and trading instruction from prominent specialists such as best-selling authors, market analysts, portfolio managers, award-winning financial journalists, and newsletter editors. MoneyShow’s interactive environment provides a unique style of live, interactive interaction for our audience of over one million passionate investors and traders, resulting in an unrivaled experience for both the expert and the investor or trader. They continue to broaden the dissemination of our expert comments through virtual events, face-to-face forums, social media, and in-depth courses that teach and advise qualified investors and traders to outperform the market, thanks to their continual network expansion. Everyone who attends each session is energized, empowered, and educated. For more information about this event, please visit https://ibn.fm/wERbk

• Since January, The Lightning Network has seen a growth rate of over 205%, according to company co-founder and CEO Shone Anstey
• Mid-November, LQwD took part in the Adopting Bitcoin – A Lightning Summit in El Salvador, a conference that brought together renowned industry experts in the Bitcoin and Lightning Network Community to discuss the future of money and payments in Central America and abroad
• LQwD announced that it spent a total of C$9.2 million (US$7.17 million) to purchase 150 Bitcoins, with an average cost of approximately C$61,000 (US$48,000) per Bitcoin. This purchase further strengthens the company’s strategic growth initiative

The Co-Founder, Chairman, and CEO of LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), Shone Anstey, was recently featured on the InvestorBrandNetwork’s The Bell2Bell Podcast to discuss his company’s business model and proven track record in the cryptocurrency industry (https://ibn.fm/GIwdY). LQwD is a financial technology company focused on the creation of an enterprise-grade infrastructure that drives Bitcoin adoption. As a Lightning Network service provider, LQwD recently released its proprietary Lightning Network Platform as a Service (“PaaS”) – lqwd.tech, which allows users to easily create a node and payment channel on the network. “We abstract away all of the complications. You hit a button, and you can integrate the API into your system and get going on the Lightning Network very, very seamlessly,” Anstey explained. “That platform is live and running; Our routing nodes help transactions get where they need to go, and, in exchange, we actually earn fees off of it. Last announced, we have 150 Bitcoin on the balance sheet, and we’re continuing to put that Bitcoin to use.” According to the LQwD CEO, the company has had a very busy year following its going public and raising over $13 million in capital to buy Bitcoin, hire more developers and launch its products. The company remains committed to improving access to the Lightning Network and offering users the possibility of conducting fast and seamless transactions, and is working toward this goal by developing strategic partnerships with key cryptocurrency wallets and exchanges. “We continue to add some key advisors from the space; we’ve signed deals with key wallets like Breez; we’ve signed deals with big exchanges such as Netcoins and continued to get our brand out there. We’ve made some big leaps and strides in an environment that is growing really quickly,” he explained, underlining that the Lightning Network itself has grown by more than 205% since January. “We’re right in the thick of it, and we’re the only public company in the world focused on the Bitcoin Lightning Network. We’re going to continue to put our stamp on that position. We have just an excellent team, which is a really big help in driving everything forward. We’ve had success in the past, and we know where we’re going with the technology,” Anstey added. To further popularize its PaaS offering, LQwD took part in the Adopting Bitcoin – A Lightning Summit in El Salvador mid-November. El Salvador is one of the few countries that adopted Bitcoin as legal tender, which contributed to much of the Lightning Network’s explosive growth this year. The conference brought together renowned industry experts in the Bitcoin and Lightning Network Community to discuss the future of money and payments in Central America and abroad (https://ibn.fm/stCAV). LQwD also took this opportunity to announce that it was increasing its Bitcoin holdings. As of the conference, LQwD spent a total of C$9.2 million (US$7.17 million) to purchase 150 Bitcoins, with an average cost of approximately C$61,000 (US$48,000) per Bitcoin. This purchase further strengthens the company’s strategic growth initiative to accumulate Bitcoin as a reserve asset. For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• Pharmaceutical company Tryp Therapeutics is advancing research into the ability to treat unmet medical needs by using synthetic psychedelic drug candidates generally regarded as illegal and of no practical value under federal drug standards
• The company is demonstrating its faith in the potential of psychedelic medicine by advancing its proprietary TRP-8802 psilocybin candidate toward Phase 2a drug trials through the FDA’s Investigational New Drug process
• The FDA has notified the company that its review of the IND for using TRP-8802 to treat fibromyalgia is complete and a trial planned in conjunction with the University of Michigan may proceed to patient enrollment
• Tryp is also preparing Phase 2a drug trials for testing TRP-8802 in treating eating disorders at the University of Florida, and for treating phantom limb pain and complex regional pain syndrome

Psychedelic drug medical research firm Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has received final U.S. Food and Drug Administration (“FDA”) approval to get under way with its planned clinical study of its synthetic psilocybin drug candidate TRP-8802 for treating fibromyalgia. “The upcoming Phase 2a study with the University of Michigan for fibromyalgia represents a significant milestone for Tryp’s clinical programs,” Tryp Chairman and CEO Greg McKee stated in the Dec. 2 announcement (https://ibn.fm/aAqGr). “We are eager to begin enrolling patients in the study next year considering the significant, unmet needs of fibromyalgia patients.” The U-M study involves 25 mg dosing of TRP-8802 and combining that with psychotherapy under the care of trained therapists to “create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect” (https://ibn.fm/yJyY8), helping the patients’ brains adapt and change beneficially so that they can overcome the deleterious effects of fibromyalgia by disrupting “neural connections that have been reported for nociplastic pain indications,” according to the announcement. The fibromyalgia study is the first of several Phase 2a trials Tryp Therapeutics anticipates for its synthetic psilocybin product. The company also plans to test TRP-8802’s efficacy in treating phantom limb pain, complex regional pain syndrome (“CRPS”) and select eating disorders. The company has already filed an Investigational New Drug (“IND”) application with the FDA for treating overeating disorders in conjunction with the University of Florida, similar to the U-M trial for fibromyalgia, but the FDA has requested some modifications to the UF project before the trial can proceed. The company is working with testing partners in the University of California’s educational system to prepare IND filings for the TRP-8802 trials treating phantom limb pain and CRPS. “Compared to other companies in the psychedelic drug development space, we’re going to have these four phase 2a clinical trials, which puts us in pretty rarefied air on top of the fact that we’re working in some therapeutic areas with patients that that really not a lot of other companies are looking at this time,” McKee said in a told Trader TV interview (https://ibn.fm/zjRTE). According to the company, its trial for examining TRP-8802’s effects on fibromyalgia patients will be one of the first of such evaluations of synthetic psilocybin in a Phase 2 study. The U-M study, under the direction of Kevin Boehnke, a research investigator in the Department of Anesthesiology and the Chronic Pain and Fatigue Research Center, will enroll 20 fibromyalgia patients for the open label clinical trial. It will establish analytical endpoints related to poor sleep quality, depression, anxiety and other conditions common to fibromyalgia patients. Following completion of the 2a trials, Tryp plans Phase 2b trials using its drug candidate TRP-8803 to more effectively alleviate pain and addiction by using a novel route of administration across the blood-brain barrier that is expected to lead to more precise control over the patient’s psychedelic experience during the treatment. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• The cannabis industry in California and the United States is undergoing a metamorphosis, reflecting scores of new marijuana markets and business opportunities for cultivators, manufacturers and retailers within the sector
• American Cannabis Partners, a multi-state, vertically integrated operator with cultivation operations across the states of Michigan and California has sought to differentiate itself through its high-quality end product
• The company, which boasts a strong personal and positive relationship with Jamaica and its people, has aligned its production processes with traditional Jamaican cultivation techniques, resulting in greater production yields, higher THC levels and more pronounced terpenes
• ACP recently revealed that it had already pre-sold the entire 2021 crop comprised of their three, patent pending cannabis strains

In June 2021, a new marijuana store was inaugurated within San Francisco’s Union City area. While a new marijuana store opening is rarely a momentous affair in California, the store in question was located within the centrally-located Union Landing shopping center, a development which also housed a Walmart, Best Buy and other high-street retail stores, marking a dramatic shift from the recent past during which cannabis retailers would be obliged to locate in less desirable industrial areas (https://ibn.fm/WPgwN). California’s legal marijuana industry has undergone a stunning transformation ever since the consumption of recreational cannabis was decriminalized in January 2018, with the new store opening in San Francisco’s Union Landing mall a clear illustration of the sector’s broadening commercial prospects and mainstream appeal. American Cannabis Partners (“ACP”), a multi-state 100% organic cannabis cultivation company headquartered within Northern California’s Emerald Triangle, has sought to capitalize on the sector’s exponential growth rates through a diversified cultivation operation spanning the United States. American Cannabis Partners has centered its business model around three key pillars: the acquisition of prime, arable, agricultural land; the development of proprietary assets; and ongoing cultivation operations. Led by a seasoned management team with over 30 years of experience within the cannabis sector, ACP now operates over 540,000 square feet of licensed canopy space for cultivation spread across the states of California and Michigan, with the company possessing the second-largest growing license within the latter state. With an ever-increasing number of North American geographies legalizing both the medical and recreational use of marijuana, cannabis research, investment, cultivation, and product development have all been evolving at a rapid pace. While much of the ongoing research has focused on the myriad potential that cannabis holds for millions suffering from a variety of health complaints around the world, cannabis producers have also sought to cater to the evolving tastes of an increasingly discerning customer base. American Cannabis Partners has designed its business model to help ensure the quality and diversity of its organic end product, a step which should assist in boosting the company’s profile and competitiveness in the event of a fully legalized U.S. market. Moreover, the company, which has long prided itself on its close personal and positive relationship with Jamaica and its people, has sought to align traditional Jamaican cultivation techniques within its cannabis cultivation, harvesting and curing process, methods which have resulted in a superior product, faster growth rates, greater production yields, higher THC levels, and enhanced terpene bouquets (https://ibn.fm/oyJb8). The level of exacting detail and care paid to their plants, as well as their adherence to sustainable Jamaican production practices, have led the company to produce some of the most sought-after flowers in the United States, with ACP recently revealing that its new, patent pending strains marketed under their wholly owned in-house ZUK brand had already seen its entire crop presold for 2021. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP

• Agriculture has massive social and economic impact in Africa: it generates up to 40% of GDP, provides livelihood for 70% of the continent’s population; expected to reach $1 trillion in value by 2030
• Still, the sector suffers from considerable inefficiencies hindering growth: low productivity, fragmented supply chains, and excessive post-harvest losses
• Tingo aims to solve these challenges for Africa’s key industry: NWASSA platform streamlines agribusiness supply chains by connecting actors in one digital marketplace, intends to provide direct connection to company’s SuperApp that offers mobile wallet

Tingo (OTCQB: IWBB), a digital service agri-fintech technology company focused on providing financial services to agriculture in Africa, appears committed to tackling some of the biggest social and economic challenges the continent faces today through its innovative technology that can uplift rural communities and open international opportunities. The importance of agriculture for the African continent cannot be overstated. It generates 20-40% of Africa’s GDP and around 70% of the continent’s population is connected to agriculture. This means that more than half a billion Africans rely on small or micro-scale farming as their main source of livelihood (https://ibn.fm/duNX6). But although agriculture is of colossal importance and is projected to grow further to become a $1 trillion industry by 2030, the sector appears considerably underfunded. It is estimated that this massive sector receives less than 3% of banking credit. Often overlooked, it now suffers from considerable inefficiencies. For example, the productivity of African agriculture is one of the lowest in the world. Also, the sector suffers from fragmented supply chains, and the post-harvest loss is considerable—in many African countries it reaches 25% of the total crop harvested. Food waste occurs primarily at the early stages of the value chain due to financial, technical, and managerial constraints in harvesting techniques and storage and cooling facilities. In Sub-Saharan Africa alone, these losses are estimated at $4 billion per year—enough to feed at least 48 million people (https://ibn.fm/Hr5AK). Challenges faced by African agriculture are considerable, but technology can help. According to the World Bank, to help African farmers grow their income, it is necessary to improve their commercialization capabilities and provide them with access to better technologies and financial tools (https://ibn.fm/G4PKp). This is where Tingo steps up to the challenge to enhance farmers’ access to appropriate tools and financial services to boost shared prosperity across the continent. Leveraging the unique ‘device as a service’ model, Tingo provides farmers with connectivity through simple smartphone technology. Tingo’s Agri-Marketplace platform NWASSA is a digital marketplace that connects actors across the agricultural value chain allowing everyone to engage in agribusiness. As the digital platform that helps deliver fresh produce from the farm to market, NWASSA streamlines agriculture supply chains and supports the economic activity in an effective and efficient way with the potential to reduce post-harvest loss. Every percentage reduction of the currently excessive post-harvest losses brings direct monetary value to farmers that use NWASSA. More importantly, through TingoPay customers have access to mobile wallets, micro-loans and other financial services all connected seamlessly to the Agri-Marketplace platform. Tingo’s revolutionary solution offers a blueprint to deliver the future of agriculture and a ‘seed to offtake’ private marketplace model that can help solve the food security challenges in Africa. As the agricultural productivity improves, this model also provides a solution that can provide import substitution, saving the countries across the continent precious foreign exchange reserves. In contrast, fragmented supply chains in sub-Saharan Africa’s agriculture currently led to a 20 to 50% markup compared to import prices (https://ibn.fm/oR6JU). Since GDP in emerging countries tends to grow when economies are driven through rural investment and growth, Tingo can catalyze massive macro and micro impact in rural communities in Africa. With the power of its proprietary Agri-Fintech platform and the scale of having almost 10 million farmers across the rural communities connected, Tingo makes these ambitious goals more achievable. For more information, visit the company’s website at www.TingoGroup.com. NOTE TO INVESTORS: The latest news and updates relating to IWBB are available in the company’s newsroom at https://ibn.fm/IWBB

• In 2020, direct sales saw record highs in sales, sellers and customers in the U.S.
• Growth across many categories within direct selling reflects broader consumer trends
• The Happy Co. is one of fastest-growing companies in the social-marketing, direct-selling industries

The resiliency of the direct-selling industry has never been more evident than during the global pandemic. Looking forward, the country’s economic situation remains fragile, but direct sales remains a bright spot on the horizon. A recent Direct Selling News article, titled “Four Reasons for Direct-Selling Optimism Post-Pandemic,” touts all that is right with the space (https://ibn.fm/sbexN) — a space in which Sharing Services Global (OTCQB: SHRG) and its direct-sales subsidiary, The Happy Co., is emerging as one of the fastest-growing companies. “Direct selling demonstrated its resilience in a challenging environment in the last year, achieving record highs in sales, sellers and customers in the U.S.,” stated the article. “As the U.S. economy continues its recovery from the pandemic, a continued rapidly evolving retail and labor market provides opportunities and challenges for direct selling, along with a few key reasons for long-term optimism.” According to the Direct Sales Association’s (“DSA”) 2021 Growth & Outlook Survey, direct-selling hit record sales last year of $40.1 billion, with 7.7 million direct sellers reaching more than 41.6 million customers throughout the year. “In the last year, direct selling was a source of in-demand products and services during a time when brick and mortar was largely shuttered and other parts of retail were slowed by significant supply chain issues,” the article reported. “You can see growth across many categories within direct selling, much of which is reflective of broader consumer trends.” As the title indicates, the article lists four major reasons that direct sales will remain a strong economic influence moving forward. First, based on several key indicators, the direct sales sector hasn’t slowed down this year. Second, growing numbers of Americans are looking for entrepreneurial, flexible earning opportunities. “Even with declining unemployment, there will likely be demand for diversified, supplemental income streams,” the article noted. “Direct selling continues to compare favorably.” Third, direct-selling companies are investing significant resources to transforming their companies virtually. Companies are working to integrate their e-commerce and mobile commerce efforts with the latest technology; they are also focusing on social selling, virtual events and faster payments. “These digital transformations likely put those companies in a stronger position to compete even as the brick and mortar reopens and retail competition ramps up,” the article observes. “The ability to combine the improved e-commerce/m-commerce/social-selling experience and its increased reach with the personal touch — that is a key differentiator for direct selling and can help drive sustained growth.” Finally, the article points to several post-pandemic retail trends that direct selling can capitalize on, including community; meeting customers with anything, anywhere, anytime; and in-person sales still representing the majority of retail for the near future. “Even though e-commerce grew at 32% last year and is expected to grow 18% this year, e-commerce only represents a fraction of overall retail,” the article stated. “The reopening of in-person shopping provides an enormous opportunity to meet customers where they are and combine the best of both worlds, leveraging the reach and convenience of online with the community, coaching, and personalization of in-person.” SHRG’s The Happy Co. is one of the fastest-growing companies in the social-marketing and direct-selling industries. The company has become the category creator for Happy Coffee and a recognized leader in natural nootropics. Sharing Services Global Corporation is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit the company’s websites at www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• SRAX reported their 3Q21 quarterly results on November 15, 2021
• The company reported 3Q21 revenues of $8.3 million, +219% YoY and +8% QoQ
• SRAX also reported that their 3Q21 EBITDA net loss narrowed to -$790k, with the company simultaneously revealing that their gross margin had widened to 78%
• SRAX’s investor intelligence platform, Sequire announced that their subscribers had swelled to 250 companies as of 3Q21, up from 225 companies at the end of the second quarter

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, recently published its third quarter 2021 quarterly results on Monday, November 15th (https://ibn.fm/vC1PH). SRAX reported third quarter revenues of $8.3 million, a figure which was up 219% year-over-year and 8% on a quarter-on-quarter basis. The company also seized on the opportunity to update their corporate revenue guidance, guiding for $10.1 million in Q4 revenues, whilst simultaneously re-affirming their fiscal year 2021 guidance and raising their target to $31.5 million. SRAX’s stellar third quarter continue a trend which has seen the company’s financial returns go from strength to strength over the past year. The company comfortably met their revised Q3 revenue guidance of $8.3 million, which had been upgraded following the release of Q2 results, whilst concurrently announcing Sequire’s 3Q21 bookings of $8.9 million, with Q4 set to rise to a record $12.5 million as of date. SRAX management revealed that they were projecting a further $4 million in Sequire bookings during the fourth quarter, a target which would drive the division’s total booked revenue in Q4 to $16.5 million and extend a run which has seen Sequire report twelve consecutive quarters of revenue growth. SRAX’s results also contained further indications of the company’s voyage towards sustainable profitability. The company reported third quarter gross margins of 78%, up from 67% in the same period last year, with their EBITDA loss declining to a mere -$790 thousand, narrowing from -$1.9 million in the third quarter of 2020. Christopher Miglino, Founder and CEO of SRAX elaborated on the results, “Our team continues to innovate on product, sales, and marketing; and this is translating into increased revenue. We will hit the high end of our 2021 guidance and are well positioned to close out 2021 strong, with an amazing 2022 on the horizon.” However, the positive earnings highlights were not limited to revenue growth alone. SRAX’s management have displayed impressive financial acuity, with cash at hand of over $34.2 million and receivables valued at $2.17mn due within 12 months (https://ibn.fm/K1yo0). With $14.3 million more liquid assets than total liabilities, the surplus suggests that the company – which boasts a net cash balance sheet, should be able to eliminate its debt without too much difficulty should it opt to do so. SRAX’s earnings announcement comes amidst a period of strong growth for the company. SRAX revealed that their Sequire investor intelligence platform had seen their number of subscribers swell to 250 public companies, a dramatic increase relative to the 225 companies on their platform in the second quarter and up from a mere 92 subscribers as of their Q3 2020 results. Moreover, and over the course of the past three months, SRAX have also launched their IR Website Builder, their SMS communication platform as well as VIRA, an IR-powered chatbot. SRAX and Sequire have also sought to provide additional value-added services to its legions of subscribers and followers with the company having successfully hosting the recent flagship and in-person LD Micro Event, an event which attracted over 750 in-person attendees and 12,000 virtual attendees. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

Date: December 6-7, 2021 Venue: Boston, MA Reimbursement executives attempt to comply with stringent commercial and public payer standards as the diagnostic industry evolves and expands into ever more specialized areas of testing. Provisions and specific evidence required to ensure coverage are always evolving, but the technology appears to be progressing even faster, posing unique hurdles in showing product value and integrating innovative diagnostics into existing payment schemes. The Diagnostic Coverage & Reimbursement conference has brought together more than 1200 industry professionals over the last ten years to discuss crucial challenges affecting diagnostic technology pricing, allowing the industry to better integrate breakthrough tests into the healthcare sector.

Topics will include:

• A Look at the Evolving Contracting & Pricing from the Payer’s Perspective Landscape
• Evaluating Health Policy and Coverage Requirements from the Payer Perspective Panel Landscape
• Putting in Place Effective Appeals Process Planning and Execution
• Administration & Legislative Guidance in Forecasting Diagnostic Tests News and Updates

The Q1 Productions Diagnostic Coverage & Reimbursement Conference will provide attendees with targeted insight into the most pressing challenges in obtaining satisfactory payments, as well as a forward-focused look at rising industry trends and their implications for reimbursement efforts in the future editions. This conference provides an unrivaled chance for delegates to maximize methods to drive successful payment by sharing thoughts on diagnostics’ place within value-based frameworks and the possibilities for new income streams by engaging with pharmaceutical firms. Attendees will engage in peer-to-peer knowledge sharing while also benefiting from direct insight into payer perspectives on coverage and payment from a variety of perspectives, including small and big manufacturers, laboratories, and public and private payers.

Why is it important?

The attendees will gain firsthand insight into current solutions through a unique encounter with expert thinking leaders. You’ll learn about current subjects directly connected to your sector through lively panel discussions, case studies, and real-world proof. Your team has access to a platform where they may ask questions of experienced industry professionals. It’s a great opportunity to expand your knowledge and perceive things in a new light. You and your team will have access to insight and interaction. Collaborate with your peers to overcome common difficulties by drawing on their knowledge and expertise. This in-person event connects you with public and private payers for direct insight into policy creation and decision-making frameworks, allowing you to extend product coverage successfully. During Q&A after peer-led case studies and success stories, avoid errors, increase market access through lessons learned, and collaborate on solutions. In engaging discussion-based sessions, build ties with decision-makers as well as diagnostic industry peers. For more information, please visit https://ibn.fm/BcNaZ

• Investment banking firm The Maxim Group reiterates ‘buy’ rating on MCURF following the company’s updates on pivotal research and technology, including The Desire Project, manufacturing of synthetic ibogaine, and the iSTRYM platform
• MINDCURE is focused on developing psychedelic compounds to scale science-backed and evidentiary-based mental health therapy worldwide
• In July, MINDCURE filed for patents on two routes of full chemical synthesis, which initiated the production of Good Laboratory Practice (“GLP”) ibogaine, which will lead to the production of Good Manufacturing Practice (“GMP”) ibogaine to scale and manufacture a global supply of its synthetic ibogaine
• In addition to this pre-clinical trial, MINDCURE has completed the draft research protocol for The Desire Project, which incorporates MDMA with psychotherapy to help treat female sexual hypoactive disorder

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, recently provided updated information on the company’s studies and clinical trials, as well as its leading technology and the latest corporate operations. Through digital therapeutics (“DTx”), MINDCURE is focused on developing psychedelic compounds to scale science-backed and evidentiary-based mental health therapy worldwide. The company’s update shares significant milestones that have been reached this year for both operating arms, MINDCURE Research and MINDCURE Technology (https://ibn.fm/SAxmI). The research arm of MINDCURE offered several updates for 2021, including important milestones in its synthetic ibogaine manufacturing. In March 2021, the company initiated chemical synthesis routes to produce fully synthetic ibogaine. In July, MINDCURE filed for patents on two routes of full chemical synthesis, which initiated the production of Good Laboratory Practice (“GLP”) ibogaine, which will lead to the production of Good Manufacturing Practice (“GMP”) ibogaine, to scale and manufacture a global supply of its synthetic ibogaine. The company is currently on schedule to provide GLP ibogaine to its research partners by Q2 2022. The pre-clinical update from MINDCURE confirms that the company intends to send ibogaine material to its pre-clinical research partner. Initially, the product will be used for broad cardiac and neurological screens, with in-depth behavioral studies possible later on. Called MSYNTH-001, the program is expected to yield initial study results during the first quarter of 2022. In addition to this pre-clinical trial, MINDCURE has completed the draft research protocol for The Desire Project, a program that incorporates MDMA with psychotherapy to help treat female Hypoactive Sexual Desire Disorder (“HSDD”). MINDCURE expects to have a pre-IND meeting with the FDA during Q1 2022 and the commencement of Phase 2 by Q3 2022. “We are proud to report that MINDCURE’s core research programs are progressing rapidly, showcasing our disciplined commitment to advancing MINDCURE’s drug research and commercial production programs,” President and CEO of MINDCURE, Kelsey Ramsden, stated. “Concurrently, we maintain a focus on identifying opportunities to expand our drug development pipeline.” The company also reported on MINDCURE Technology operational segment milestones, more specifically on the iSTRYM digital platform’s progress. In August 2021, MINDCURE released the minimum viable product version of its digital therapeutics technology to partner clinics across North America, with great success – the company has so far partnered with 20 ketamine clinics in nine different states in the U.S. and three Canadian provinces. Continuing to work toward becoming a leader in the distribution of high-quality therapy protocols through iSTRYM, the company plans to commence full commercial deployment of its digital therapeutics platform to partner clinics early next year, while also planning to expand to Europe and the UK by Q4 2022. Corporate-wise, the company announced that it granted 30,000 stock options to certain employees and that it engaged the services of Sandstone Media LLC for comprehensive marketing and media strategy and services, including product and brand awareness, content creation, social media, advertising, and more. A day after MINDCURE released its update, leading investment banking and wealth management firm The Maxim Group reiterated a ‘buy’ rating for the company, noting the progress achieved across its research and technology programs and pipeline, from iSTRYM to ibogaine and The Desire Project. In its analysis report, The Maxim Group underlined that it is key for the company in 2021 to continue with the block and tackle approach. This approach puts the company in the best position in the evolving psychedelic-based medicine space, the report says. According to the investment bank, even if share value dropped in 2021, all the pieces should fall into place for MINDCURE shares to do well in 2022. For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF Forward-Looking Information Certain information presented in this article may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases. Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; the Company will develop its products as expected and that they will attain the outcomes anticipated; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that strategic partnerships entered by the Company will create the opportunities and outcomes anticipated; that MINDCURE will advance wellness worldwide; that trading on the OTCQX will attract additional investment and provide additional liquidity for shareholders. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: successful clinical studies relating to ibogaine and the Desire Project, successfully synthesizing and manufacturing of ibogaine, the successful development, integration and deployment of iSTRYM, the successful development of appropriate Ketamine protocols, and acquiring adequate protection of any IP developed. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release. For further information MINDCURE Investor Relations investors@mindcure.com 1-888-593-8995 Media Inquiries Annie Graf / Kristin Cwalinski KCSA Strategic Communications